<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: May 19, 1998
--------------
UROMED CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 000-23266 04-3104185
- - ----------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
Identification Number)
64 A Street, Needham, Massachusetts 02194
------------------------------------------
Address of principal executive offices
Registrant's telephone number, including area code: (781) 433-0033
--------------
<PAGE>
Item 5. Other Events
On May 15, 1998, the Registrant issued a press release announcing a
restructuring of its operations.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
Exhibit Number Description
-------------- -----------
99.1 Press Release issued May 15, 1998 announcing
a stockholder approval of reverse stock split.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
UROMED CORPORATION
Dated: May 19, 1998 By: /s/Paul J. Murphy
-------------------------
Paul J. Murphy, Treasurer and
Chief Financial Officer
<PAGE>
Exhibit 99.1
UroMed Corporation
64 A Street
Needham, MA 02194
(617) 433-0033 Fax (617) 433-0032
FOR IMMEDIATE RELEASE
Corporate Investor Contact: Corporate Media Contact:
Kristen Galfetti Larry Cronin
Manager, Investor Relations Director, Marketing Communications
Tel: (781) 433-0033 Ext. 329 Tel: (781) 433-0033 Ext. 252
UroMed Corporation Stockholders Approve Reverse Stock Split
NEEDHAM, MA, May 15, 1998 - UroMed Corporation (NASDAQ:URMD) announced
today that at the 1998 meeting of shareholders held this morning, shareholders
approved a one-for-five reverse stock split. The company expects the reverse
split to take effect before trading begins on May 19, 1998. The reverse split
will reduce the company's outstanding shares to approximately 5 million, from
26.8 million shares outstanding. The reverse stock split action was taken to
meet Nasdaq's continued listing requirements.
UroMed, founded in October 1990, is dedicated to establishing itself
as a leader in the development of male and female healthcare products. UroMed
has developed or acquired technology in three core areas: prostate cancer,
urinary incontinence, and breast cancer. UroMed's direct hospital-based
business lines include its CaverMap-TM- Surgical Aid, intended to aid
physicians in preserving vital nerves during prostate cancer surgery, Iodine125
prostate cancer brachytherapy seeds and its BEACON Technology System-TM-, a
minimally invasive incontinence surgical line. UroMed's office-based continuum
of continence care product lines include the Reliance-Registered Trademark-
Insert, the INTROL-Registered Trademark- BladderNeck Support Prosthesis, and
the Impress-TM- Softpatch. In breast cancer screening, UroMed is developing
its investigational BreastExam-TM-, BreastCheck-TM- and Breast View-TM-
electronic palpation technology in order to aid physicians and patients in the
important mission of finding suspicious breast lumps earlier. UroMed also
continues to dedicate resources to the development and/or acquisition of
product lines that fit into UroMed's strategic platform.
###
INTROL-Registered Trademark- Bladder Neck Support Prosthesis and Reliance-
Registered Trademark- Urinary Control Insert are registered trademarks of
UroMed Corporation. Impress-TM- Softpatch, PelvicFlex-TM- Personal Trainer
Video , BEACON Technology System-TM-, BreastCheck-TM- BreastExam-TM-
BreastView-TM- and CaverMap-TM- Surgical Aid are trademarks of UroMed
Corporation.
